(UroToday.com) The 2025 ESMO annual meeting featured a biomarker-based personalization in metastatic prostate cancer session and a presentation by Dr. Alice Bernard-Tessier discussing targeting ...

Phase III Evaluation of Mevrometostat + Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (MEVPRO-1 & MEVPRO-2) A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN ...

(UroToday.com) The 2025 SNMMI annual meeting featured a prostate cancer session and a presentation by Dr. Adrien Holzgreve discussing a clinical trial protocol update of FLEX-MRT, a randomized phase 2 ...

The 2026 GU ASCO annual meeting featured a renal cell carcinoma session and a discussant presentation by Dr. Beckermann, ...

Based on the NCCN 1.2026 guidelines for the management of CSI seminoma, surveillance is strongly preferred for pT1-pT3 tumors ...

The 2026 GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Tyler F. Stewart ...

ASCO GU 2026, Advanced Urothelial Bladder Cancer, FGFR3 genomic alterations in liquid biopsies, FoundationOne CDx assay, FGFR3 mutation.

(UroToday.com) The 2026 GU ASCO annual meeting featured a urothelial carcinoma session and a presentation by Dr. Jan-Jaap Mellema discussing results from the phase 2 Indi-Blade trial assessing ...

(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr.

Patients with advanced clear cell RCC whose disease progressed after 1-3 prior systemic therapies (including an anti–PD- [L]1 therapy) were randomly assigned 1:1 to belzutifan 200 mg or 120 mg daily: ...

The 2026 GU ASCO annual meeting featured a testicular cancer session and a presentation by Dr. Jennifer King discussing a ...